Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNV108 phase 1 study in healthy adults and patients with diabetic peripheral neuropathy
NL-OMON58843Phase 1Active, not recruiting
- Sponsor
- Tenvie Therapeutics
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of TNV108 in diabetic polyneuropathy (DPN) (2 arms), sponsored by Tenvie Therapeutics. Primary endpoint: Safety and tolerability. Started Mar 2026; status: active, not recruiting.
02
Drugs
TNV108
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NL-OMON58843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58843.